International AMR Action! 21 Sep Wellcome Trust-UNGA event / 12-13 Oct Call to Action (Berlin)

Dear All: 

The international conversation continues apace following the recent DRIVE-AB meeting on antibiotic incentives. There are two further important meetings coming up that you may wish to know about.

First, Wellcome Trust is co-hosting a side-event with the UN Foundation during the UN General Assembly on 21 Sep (yes, this week!). The side event is from 8a-10a in New York City. Here is the registration link should you be in NYC on Thursday and able to attend. Panel discussions will focus on the challenges of developing multi-sectoral national action plans as well as covering progress on support mechanisms for antibiotic discovery. The keynote speakers look wonderful, including opening comments from the WHO’s DG:

  • Session title: One Year On: Progress, Challenges, Opportunities, and New Ways of Working to Tackle Antimicrobial Resistance (AMR)
  • Keynote: Dr. Tedros Adhanom Ghebreyesus; Director-General, World Health Organization; Co-Chair, UN Interagency Coordination Group on AMR
  • Keynote: Professor Dame Sally Davies; Chief Medical Officer, United Kingdom; Co-Convener, UN Interagency Coordination Group
  • Keynote: Ms. Maria Helena Semedo; Deputy Director-General, Food and Agriculture Organization of the United Nations
  • Closing: Honorable Dr. Aaron Motsoaledi; Minister of Health, South Africa

Second, Wellcome Trust is also organizing an AMR Call to Action Conference 12-13 October in Berlin. The event is “… an opportunity for national governments and multilateral institutions to come together with the civil society, private and philanthropic sectors to focus on the most critical gaps in tackling the development and spread of drug-resistant infections, and to commit to concerted and tangible actions.” If you think you might be interested in attending (it is invitation-only but I am told there is still some scope to add attendees), please contact Wellcome Trust by email at amrcalltoaction@wellcome.ac.uk.

It is fabulous to see these conversations at the political level … I know that we don’t yet have all the tools we need to ensure a vibrant antibiotic pipeline, but these conversations are the necessary prelude!

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

Share

CDC-FDA webinar: Developing drugs to prevent healthcare-associated infections (30 Aug 2022)

Dear All, A quick note today to call your attention to an upcoming webinar that will be of wide interest. Substantial new details have been added to the online agenda materials for the 30 August 2022 (virtual, 8.30a-5.00p ET) webinar sponsored by CDC and FDA entitled “Drug Development Considerations for the Prevention of Healthcare-Associated Infections.” This is very

US Senate and House / Call for Pull incentives in FY23 budget

Dear All, The US Government is now building its budget for FY23 (Federal Year 2023, really runs 1 Oct 22 to 30 Sep 23). We had proposals from the House for the Department of Health and Human Services (DHHS) budget in late June;  and the proposal from Senate was released on 28 Jul 2022. Each

WHO Vaccine pipeline review; CDC on impact of COVID on AMR

Dear All, WHO continues to crank out those pipeline reviews … now we have one for bacterial vaccines! Go here for the press release and here for the report. The report considers data from 2010 forward and (interestingly) provides data on both active and failed projects. The review identified 94 active preclinical candidates and 61

IDWeek 2022: New pipeline sessions seek presentation of therapeutics and diagnostics!

Dear All: I have learned that the program for IDWeek 2022 will have specific dedicated pipeline sessions for therapeutics and diagnostics. The online details are relatively scant, but my understanding is that the therapeutics of interest for these sessions include antibacterials, antifungals, and non-HIV, non-COVID antiviral agents. There do not appear to be any constraints

Scroll to Top